Clinical Trial Update: Study to Evaluate the Safety and Efficacy of IM19 CAR-T Cells in Patients With Relapsed and Refractory (R/R) Mantle Cell Lymphoma [Phase 1, Phase 2]

View source ↗

Summary

A multi-phase (Phase 1/2) clinical trial evaluating IM19 CAR-T cells for relapsed/refractory mantle cell lymphoma is ongoing; status currently unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lymphoma
• Mantle Cell Lymphoma

Drugs mentioned

• IM19 CAR-T Cells

Snippet

Sponsor: Beijing Immunochina Medical Science & Technology Co., Ltd. | Conditions: Lymphoma, Lymphoma, Mantle-Cell | Phase 1, Phase 2 | Status: UNKNOWN